Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral: Vanier Canada Graduate Scholarships

University of Toronto

$150,000.00

Delivery of traceable, multifunctional, biomimetic nanoparticles to the brain to treat Alzheimer's disease

EF 2014-15

Résumé
Alzheimer's disease is a prevalent neurological disorder with no cure that yields devastating implications, including memory loss and ultimately premature death, for the 500, 000 Canadian individuals it and its related dementias afflict. Without the discovery of a curative intervention in the face of an aging Canadian population, it is expected that the number of Canadians affected by Azheimer's disease will double in less than 25 years. It is thus imperative that a suitable therapy is found which addresses the two major challenges in Alzheimer's disease drug discovery: 1) bypassing the blood-brain barrier (BBB), which prevents the passage of therapeutic agents from the blood stream into the brain, and 2) preventing and clearing the accumulation of toxic proteins and plaques in the brain that are the source of the disease. This project aims to develop a mutipurpose organic nanoparticle and ultrasound-based system that overcomes these two challenges. This technology addresses the first hurdle via the use of focussed ultrasound, which temporarily opens the BBB to allow the nanoparticles to pass into the diseased brain tissue. There, the nanoparticles are expected to address the second challenge in Alzheimer's disease therapy generation through the incorporation of the protein apolipoprotein E3, which naturally clears the toxic plaques responsible in part for disease progression. This protein will be used alongside a porphyrin, a molecule naturally present in red blood cells, in a unique fashion to generate a non-toxic particle that resembles the body's "good cholesterol", HDL. Not only does this nanoparticle-ultrasound system possess the potential to cross the BBB and clear Alzheimer's disease, it has the ability to do so in a manner that can be imaged via the porphyrin molecules in order to validate successful therapy delivery. Thus, the proposed nanotechnology holds great promise in both Alzheimer's disease treatment and the confirmation of its success.
Programme
Doctoral: Vanier Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
318251
Name
Rajora Maneesha A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Delivery of traceable, multifunctional, biomimetic nanoparticles to the brain to treat Alzheimer's disease
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Alzheimer'S Disease; Drug-Delivery; Mri-Guided Focused Ultrasound; Nanomedicine; Optical Imaging
Abstract
Alzheimer's disease is a prevalent neurological disorder with no cure that yields devastating implications, including memory loss and ultimately premature death, for the 500, 000 Canadian individuals it and its related dementias afflict. Without the discovery of a curative intervention in the face of an aging Canadian population, it is expected that the number of Canadians affected by Azheimer's disease will double in less than 25 years. It is thus imperative that a suitable therapy is found which addresses the two major challenges in Alzheimer's disease drug discovery: 1) bypassing the blood-brain barrier (BBB), which prevents the passage of therapeutic agents from the blood stream into the brain, and 2) preventing and clearing the accumulation of toxic proteins and plaques in the brain that are the source of the disease. This project aims to develop a mutipurpose organic nanoparticle and ultrasound-based system that overcomes these two challenges. This technology addresses the first hurdle via the use of focussed ultrasound, which temporarily opens the BBB to allow the nanoparticles to pass into the diseased brain tissue. There, the nanoparticles are expected to address the second challenge in Alzheimer's disease therapy generation through the incorporation of the protein apolipoprotein E3, which naturally clears the toxic plaques responsible in part for disease progression. This protein will be used alongside a porphyrin, a molecule naturally present in red blood cells, in a unique fashion to generate a non-toxic particle that resembles the body's "good cholesterol", HDL. Not only does this nanoparticle-ultrasound system possess the potential to cross the BBB and clear Alzheimer's disease, it has the ability to do so in a manner that can be imaged via the porphyrin molecules in order to validate successful therapy delivery. Thus, the proposed nanotechnology holds great promise in both Alzheimer's disease treatment and the confirmation of its success.
Competitiondate
201411
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Rajora, Maneesha A
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~